Form 8-K

8-K — Lifeway Foods, Inc.

Accession: 0001683168-26-003934

Filed: 2026-05-14

Period: 2026-05-14

CIK: 0000814586

SIC: 2020 (DAIRY PRODUCTS)

Item: Entry into a Material Definitive Agreement

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — lifeway_8k.htm (Primary)

EX-1.1 — UNDERWRITING AGREEMENT (lifeway_ex0101.htm)

EX-5.1 — OPINION (lifeway_ex0501.htm)

EX-99.1 — PRESS RELEASE DATED MAY 14, 2026 (lifeway_ex9901.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: lifeway_8k.htm · Sequence: 1

LIFEWAY FOODS, INC. 8-K

false

0000814586

2026-05-14

0000814586

LWAY:CommonStockNoParValueMember

2026-05-14

0000814586

LWAY:PreferredStockPurchaseRightsMember

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 14, 2026

LIFEWAY FOODS, INC.

(Exact Name of Registrant as Specified in Its

Charter)

ILLINOIS

000-17363

36-3442829

(State or

Other Jurisdiction of

Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

6431

West Oakton St. Morton

Grove, IL

60053

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including

area code: (847) 967-1010

N/A

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

Common Stock, no par value

LWAY

The Nasdaq Stock Market

Preferred Stock Purchase Rights

None

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b 2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Definitive Material Agreement.

Underwriting Agreement

On May 14, 2026, Lifeway Foods, Inc. (the “Company”) entered

into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC (the “Underwriter”) and Danone USA

Public Benefit Corporation (the “Selling Stockholder”) in connection with a public offering of an aggregate of 3,454,756 shares

(the “Shares”) of the Company’s common stock, no par value (the “Common Stock”), by the Selling Stockholder

at a price to the public of $19.50 per share (the “Offering”).

The Offering is being made pursuant to a shelf registration statement

on Form S-3 (No. 333-291148) that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective

by the SEC on December 10, 2025 and a prospectus supplement.

The closing of the Offering is expected to occur on or about May

19, 2026, subject to the satisfaction of customary closing conditions. The Company will not receive any proceeds from the Offering. The Company has agreed to repurchase approximately $5.0 million of the Shares in the Offering at the same per

share price to be paid by investors in the Offering (the “Share Repurchase”). The Offering is not conditioned upon the

completion of the Share Repurchase, but the share repurchase is conditioned upon the completion of the Offering.

BTIG, LLC is acting as sole underwriter for the Offering.

The foregoing description of the Underwriting Agreement does not purport

to be complete and is qualified in its entirety by reference to, and incorporate herein by reference, the full text thereof, a copy of

which is filed herewith as Exhibit 1.1.

Item 8.01. Other Events.

On May 14, 2026, the Company issued a press release announcing the

pricing of the Offering, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

1.1

Underwriting Agreement dated May 14, 2026.

5.1

Opinion of Kelley Drye & Warren LLP regarding legality of securities being registered.

23.1

Consent of Kelley Drye & Warren LLP (included in Exhibit 5.1).

99.1

Press Release dated May 14, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIFEWAY FOODS, INC.

Date: May 14, 2026

By:

/s/ Eric Hanson

Name:

Eric Hanson

Title:

Chief Financial and Accounting Officer

EX-1.1 — UNDERWRITING AGREEMENT

EX-1.1

Filename: lifeway_ex0101.htm · Sequence: 2

Exhibit 1.1

3,454,756 Shares

LIFEWAY FOODS, INC.

Common Stock, No Par Value

UNDERWRITING AGREEMENT

May 14, 2026

BTIG, LLC

65 East 55th Street

New York, NY 10022

Ladies and Gentlemen:

Danone USA Public Benefit

Corporation, a Delaware public benefit corporation (the “Selling Stockholder”), proposes to sell to BTIG, LLC (“BTIG”),

as the sole underwriter (the “Underwriter,” which term shall also include any underwriter substituted as hereinafter provided

in Section 10 hereof), 3,454,756 shares of common stock, no par value per share (the “Common Shares”) of Lifeway Foods,

Inc., a corporation organized under the laws of the State of Illinois (the “Company”). For purposes of this Agreement, the

term “Representative” as used herein shall mean BTIG, as Underwriter, and the term “Underwriters” shall mean

either the singular or the plural, as the context requires. The 3,454,756 Common Shares to be sold by the Selling Stockholder are called

the “Offered Shares.”

The Company and the Selling

Stockholder understand that the Underwriter proposes to make a public offering of the Offered Shares as soon as the Representative deems

advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered.

The Company has prepared and

filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 (No.

333-291148) covering the Offered Shares, under the Securities Act of 1933, as amended (the “Securities Act”) and rules

and regulations promulgated thereunder (the “Securities Act Regulations”), which shelf registration statement was declared

effective by the Commission. Such registration statement, as of any time, means such registration statement as amended by any post-effective

amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to

be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the Securities Act and the documents otherwise

deemed to be a part thereof as of such time pursuant to Rule 430B under the Securities Act Regulations (“Rule 430B”),

and is referred to herein as the “Registration Statement;” provided, however, that the “Registration Statement”

without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the

first contract of sale for the Offered Shares, which time shall be considered the “new effective date” of such registration

statement with respect to the Offered Shares within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules

thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form

S-3 under the Securities Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B. Each preliminary

prospectus used in connection with the offering of the Offered Shares, including the documents incorporated or deemed to be incorporated

by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, are collectively referred to herein as a “preliminary

prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus supplement

relating to the Offered Shares in accordance with the provisions of Rule 424(b) under the Securities Act Regulations (“Rule 424(b)”).

The final prospectus, in the form first furnished or made available to the Underwriter for use in connection with the offering of the

Offered Shares, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3

under the Securities Act, are collectively referred to herein as the “Prospectus.” For purposes of this Agreement,

all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the

foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval

system or any successor system (“EDGAR”).

As used in this Agreement:

“Applicable

Time” means 8:30 A.M., New York City time, on May 14, 2026 or such other time as agreed by the Selling Stockholder and the Representative.

“General

Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most

recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the

Applicable Time and the information included on Schedule B-1 hereto, all considered together.

“Issuer

Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 under the Securities

Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in

Rule 405 under the Securities Act Regulations (“Rule 405”)) relating to the Offered Shares that is (i) required to

be filed with the Commission by the Company, (ii) a “road show for an offering that is a written communication” within the

meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission

pursuant to Rule 433(d)(5)(i) because it contains a description of the Offered Shares or of the offering that does not reflect the final

terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained

in the Company’s records pursuant to Rule 433(g).

“Issuer

General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective

investors (other than a “bona fide electronic road show,” as defined in Rule 433 (a “Bona Fide Electronic

Road Show”)), as evidenced by its being specified in Schedule B-2 hereto.

“Issuer

Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing

Prospectus.

“Testing-the-Waters

Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the

Securities Act or Rule 163B under the Securities Act Regulations.

“Written

Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning

of Rule 405 under the Securities Act Regulations.

All references in this Agreement

to financial statements and schedules and other information which is “contained,” “included” or “stated”

(or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include

all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration

Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and

all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus

shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

and the rules and regulations promulgated thereunder (the “Exchange Act Regulations”), incorporated or deemed to be

incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after

the execution and delivery of this Agreement.

SECTION 1.

Representations and Warranties.

(a)

Representations and Warranties by the Company. The Company represents and warrants to the Underwriter as of the date hereof,

the Applicable Time, the Closing Time (as defined below), and agrees with the Underwriter, as follows:

(i)

Registration Statement and Prospectuses. At the time the Company’s Annual Report on Form 10-K for the year ended December

31, 2025 (the “Annual Report”) was filed with the Commission, or, if later, at the time the Registration Statement

was originally filed with the Commission, the Company met, and the transactions contemplated by this Agreement meet, the requirements

for and comply with the conditions for the use of Form S-3 under the Securities Act, including General Instruction I.B.1 of Form S-3.

Each of the Registration Statement and any post-effective amendment thereto has been declared effective by the Commission under the Securities

Act and the Securities Act Regulations. No stop order suspending the effectiveness of the Registration Statement or any post-effective

amendment thereto has been issued by the Commission under the Securities Act, no order preventing or suspending the use of any preliminary

prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been instituted by the

Commission or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with any requests

from the Commission for additional information.

Each of the Registration

Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effect date with respect to the

Underwriters pursuant to Rule 430B(f)(2) under the Securities Act Regulations, complied in all material respects with the requirements

of the Securities Act and the Securities Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement

thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act

and the Securities Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering

and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR,

except to the extent permitted by Regulation S-T. The documents incorporated or deemed to be incorporated by reference in the Registration

Statement and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied

and will comply in all material respects with the requirements of the Exchange Act and the Exchange Act Regulations.

The Registration

Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and

the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been

duly executed pursuant to such authorization.

(ii)

Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time, at the Closing

Time, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact

required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, none of (A) the General

Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure

Package, nor (C) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package,

included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus

nor any amendment or supplement thereto (including any prospectus wrapper), as of its date, at the time of any filing with the Commission

pursuant to Rule 424(b), at the Closing Time, included, includes or will include an untrue statement of a material fact or omitted, omits

or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which

they were made, not misleading.

The documents incorporated

or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time

the Registration Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case

may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus,

as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be

stated therein or necessary to make the statements therein not misleading.

The representations

and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto),

the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance

upon and in conformity with written information furnished to the Company by the Underwriter through the Representative expressly for use

therein. For purposes of this Agreement, the only information so furnished shall be the information in paragraphs six, twelve, thirteen,

fourteen, fifteen and sixteen under the heading Underwriting in the Prospectus (collectively, the “Underwriter Information”).

(iii)

Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained

in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other

prospectus deemed to be a part thereof that has not been superseded or modified. No filing of any “road show” (as defined

in Rule 433(h)) is required in connection with the offering of the Offered Shares. Any Issuer Free Writing Prospectus that the Company

is required to file pursuant to Rule 433(d) has been, or will be, filed with the Commission in accordance with the requirements of the

Securities Act and the Securities Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file,

pursuant to Rule 433(d) or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material

respects with the requirements of the Securities Act and the Securities Act Regulations. Except for the Issuer General Use Free Writing

Prospectuses, if any, and electronic road shows, if any, each furnished to the Representative before first use, the Company has not prepared,

used or referred to, and will not, without the prior consent of the Representative, prepare, use or refer to, any Issuer Free Writing

Prospectus.

(iv)

Testing-the-Waters Materials. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters

Communications with the consent of the Representative with entities that are or the Company reasonably believes to be qualified institutional

buyers within the meaning of Rule 144A under the Securities Act Regulations or institutions that are accredited investors within the meaning

of Rule 501 under the Securities Act Regulations and (B) has not authorized anyone other than the Representative to engage in Testing-the-Waters

Communications. The Company reconfirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters

Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule B-3

hereto. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or

development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material

fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances

existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement,

at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

(v)

Distribution of Offering Material by the Company. Prior to the completion of the Underwriter’s distribution of the

Offered Shares, the Company has not distributed and will not distribute any offering material in connection with the offering and

sale of the Offered Shares other than the Registration Statement, the General Disclosure Package, the Prospectus or any free writing prospectus

reviewed and consented to by the Representative, the Issuer Free Writing Prospectus hereto and any Testing-the-Waters Communication.

(vi)

Company Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto,

at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of

Rule 164(h)(2) under the Securities Act Regulations) of the Offered Shares and at the date hereof, the Company was not and is not an “ineligible

issuer,” as defined in Rule 405 under the Securities Act Regulations, without taking account of any determination by the Commission

pursuant to Rule 405 under the Securities Act Regulations that it is not necessary that the Company be considered an ineligible issuer.

(vii)

Independent Accountants. The accountants who certified the financial statements and supporting schedules included in the

Registration Statement, the General Disclosure Package and the Prospectus are Grant Thornton LLP, who (i) are independent public accountants

as required by the Securities Act, the Securities Act Regulations, the Exchange Act, the rules and regulations of the Commission under

the Exchange Act and the Public Company Accounting Oversight Board (United States) (“PCAOB”), (ii) are in compliance

with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act,

and (iii) are a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who

has not requested such registration to be withdrawn. Such accountants have not been engaged by the Company to perform any “prohibited

activities” or provided to the Company any “non-audit services” (as defined in Section 10A of the Exchange Act).

(viii)

Financial Statements; Non-GAAP Financial Measures. The financial statements included or incorporated by reference in the

Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, comply as to

form in all material respects with Regulation S-X under the Securities Act and present fairly, in all material respects, the financial

position of the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the statement of operations, stockholders’

equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been

prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout

the periods involved. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information

required to be stated therein. No other financial statements or supporting schedules are required to be included in the Registration Statement,

the General Disclosure Package or the Prospectus. No historical or pro forma financial statements or supporting schedules are required

to be included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus under the

Securities Act or the Securities Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package

or the Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined

by the rules and regulations of the Commission) comply with Regulation G under the Exchange Act, and Item 10 of Regulation S-K under the

Exchange Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference

in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material

respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. To the Company’s

knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed

to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of,

or audited, the financial statements, supporting schedules or other financial data filed with the Commission and included in the Registration

Statement, the General Disclosure Package and the Prospectus.

(ix)

Off Balance Sheet Transactions. There are no transactions, arrangements and other relationships between and/or among the

Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to,

any structured finance, special purpose or limited purpose entity (each, an “Off Balance Sheet Transaction”) that would

affect materially the Company’s liquidity or the availability of or requirements for its capital resources, including those Off

Balance Sheet Transactions described in the Commission’s Statement about Management’s Discussion and Analysis of Financial

Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Registration Statement,

the General Disclosure Package and the Prospectus which have not been described as required.

(x)

Sarbanes-Oxley Act of 2002. There is and has been no failure on the part of the Company or any of the Company’s directors

or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and

the rules and regulations promulgated thereunder (collectively, the “Sarbanes-Oxley Act”), including Section 402 related

to loans and Sections 302 and 906 related to certifications.

(xi)

No Material Adverse Change in Business. Since the respective dates as of which information is given in the Registration

Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse change, or any development that could

be expected to result in a material adverse change, in (1) the condition, financial or otherwise, or in the earnings, business affairs

or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course

of business or (2) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations

hereunder (any such change being referred to herein as a “Material Adverse Effect”), (B) there have been no transactions

entered into by the Company or any of its Subsidiaries, other than those in the ordinary course of business, which are material with respect

to the Company and its Subsidiaries considered as one enterprise, (C) there have been no material liabilities or obligations, direct or

contingent, entered into by the Company or any of its Subsidiaries, (D) there has been no material decrease in capital stock and no material

increase in any short-term or long-term indebtedness of the Company or any of its Subsidiaries and (E) there has been no dividend

or distribution of any kind declared, paid or made by the Company on any class of its capital stock, or, except for dividends paid to

the Company or another Subsidiary, by any Subsidiary on any class of shares, or any repurchase or redemption by the Company or any of

its Subsidiaries of any class of shares.

(xii)

Good Standing of the Company. The Company has been duly organized and is validly existing as a corporation in good standing

under the laws of the State of Illinois and has corporate power and authority to own, lease and operate its properties and to conduct

its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform

its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing

in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct

of business, except where the failure to be so qualified or to be in good standing could not reasonably be expected, individually or in

the aggregate, to have a Material Adverse Effect.

(xiii)

Subsidiaries of the Company. Each subsidiary of the Company listed on Schedule 1(a)(xiii) (each, a “Subsidiary”

and, collectively, the “Subsidiaries”) has been duly organized and is validly existing in good standing under the laws

of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties

and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly

qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason

of the ownership or leasing of property or the conduct of business. All of the issued and outstanding capital stock of each Subsidiary

has been duly authorized and validly issued, is fully paid and non-assessable and is owned by the Company, directly or through Subsidiaries,

free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital

stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The Company

does not own or control, directly or indirectly, any corporation, association or other entity other than the Subsidiaries listed in Exhibit

21 to the Annual Report. No Subsidiary is prohibited or restricted, directly or indirectly, from paying dividends to the Company, from

making any other distribution with respect to such Subsidiary’s equity securities, from repaying to the Company or any other Subsidiary

any amounts that may from time to time become due under any loans or advances to such Subsidiary from the Company or from transferring

any property or assets to the Company or to any other Subsidiary.

(xiv)

Capitalization. The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration

Statement, the General Disclosure Package and the Prospectus (except for subsequent issuances, if any, (A) pursuant to this Agreement,

(B) pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement, the General Disclosure Package

and the Prospectus or (C) pursuant to the conversion of convertible securities or exercise of options referred to in the Registration

Statement, the General Disclosure Package and the Prospectus). The Common Shares conform in all material respects to the description thereof

incorporated by reference into the Registration Statement, the General Disclosure Package and the Prospectus, including as an exhibit

entitled “Description of Securities.” The outstanding shares of capital stock of the Company have been duly authorized and

are validly issued, fully paid and non-assessable. Except as set forth on Schedule 1(a)(xiv), none of the outstanding shares of capital

stock of the Company was issued in violation of the preemptive rights, rights of first refusal or other similar rights of any securityholder

of the Company. Except as disclosed in or contemplated by the Registration Statement, the General Disclosure Package and the Prospectus,

there are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity

or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or its Subsidiaries.

(xv)

Authorization of Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(xvi)

Authorization and Description of Offered Shares. The Offered Shares to be purchased by the Underwriters from the Selling

Stockholder are duly authorized, validly issued and fully-paid and non-assessable. The Common Shares conform to all statements relating

thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms to the

rights set forth in the instruments defining the same. No holder of Offered Shares will be subject to personal liability by reason of

being such a holder.

(xvii)

Registration Rights. Other than the registration rights of the Selling Stockholder pursuant to the Cooperation Agreement

dated September 30, 2025 between the Company and the Selling Stockholder (the “Cooperation Agreement”) and the Stockholders’

Agreement dated October 1, 1999 (as amended, the “Stockholders’ Agreement”), there are no persons with registration

rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered

for sale or sold by the Company under the Securities Act pursuant to this Agreement, other than those rights that have been disclosed

in the Registration Statement, the General Disclosure Package and the Prospectus and have been duly waived.

(xviii)

No Rights to Purchase Preferred Stock. The issuance and sale of the Offered Shares as contemplated hereby will not cause

any holder of any shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants

or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred

stock of the Company.

(xix)

Absence of Violations, Defaults and Conflicts. Neither the Company nor any Subsidiary is (A) in violation of its charter,

by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or

condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument

to which the Company or any Subsidiary is a party or by which either of them may be bound or to which any of the properties or assets

of the Company or any Subsidiary is subject (collectively, “Agreements and Instruments”), except for such defaults

that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, or (C) in violation of any

law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative

agency or other authority, body or agency having jurisdiction over the Company or its Subsidiaries or any of their respective properties,

assets or operations (each, a “Governmental Entity”), except for such violations that could not reasonably be expected,

individually or in the aggregate, to have a Material Adverse Effect. The execution, delivery and performance of this Agreement and the

consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus

and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and

will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default

or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties

or assets of the Company or its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults

or Repayment Events or liens, charges or encumbrances that could not reasonably be expected, individually or in the aggregate, to have

a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, by-laws or similar organizational

document of the Company or its Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental

Entity. As used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture

or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption

or repayment of all or a portion of such indebtedness by the Company or its Subsidiaries.

(xx)

No Contract Terminations. Neither the Company nor any of its Subsidiaries has sent or received any communication regarding

termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Registration Statement, the

General Disclosure Package and the Prospectus, and no such termination or non-renewal has been threatened by the Company or any of its

Subsidiaries or, to the Company’s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal

has not been rescinded as of the date hereof.

(xxi)

Related-Party Transactions. There are no relationships, direct or indirect, or related-party transactions involving the

Company or any of its Subsidiaries or any other person (including any director, officer, stockholder, customer or supplier of the Company

or any of its Subsidiaries) required to be described in the Registration Statement, the General Disclosure Package or the Prospectus that

have not been described as required. There are no material outstanding loans, advances (except normal advances for business expenses in

the ordinary course of business) or guarantees of indebtedness by the Company or any of its Subsidiaries to or for the benefit of any

of the officers or directors of the Company or any of its Subsidiaries, or any of the family members of any of such persons.

(xxii)

Exchange Act Registration; Listing. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and the

Common Shares have been approved for listing on The Nasdaq Global Market (the “Exchange”), and the Company has taken

no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting

the Common Shares from the Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating

terminating such registration or listing. The Company is in compliance with all applicable listing requirements of the Exchange.

(xxiii)

Absence of Labor Dispute. No labor dispute with the employees of the Company or its Subsidiaries exists or, to the knowledge

of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its

or its Subsidiaries’ principal collaborators, suppliers, manufacturers, customers or contractors, which, in either case, would result

in a Material Adverse Effect. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, none

of the employees of the Company or any of its Subsidiaries is represented by a labor union and, to the knowledge of the Company, no labor

union organizing activities have occurred or are ongoing. Neither the Company nor its Subsidiaries has violated (or received notice of

any violation of) any federal, state or local law or foreign law relating to the discrimination in hiring, promotion or pay of employees,

nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous foreign laws and regulations, which could

reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect.

(xxiv)

Absence of Proceedings. There is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental

Entity (including, without limitation, any action, suit, proceeding, inquiry or investigation before or brought by the U.S. Food and Drug

Administration (the “FDA”) now pending or, to the knowledge of the Company, threatened against or affecting the Company

or its Subsidiaries, which could reasonably be expected to result in a Material Adverse Effect, or which could reasonably be expected

to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this

Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings

to which the Company or any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are

not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation

incidental to the business, could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(xxv)

Accuracy of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement,

the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described

and filed as required.

(xxvi)

No Consents Required. Except for the registration of the Offered Shares under the Securities Act and the Exchange Act and

applicable state securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required

by FINRA and the Exchange in connection with the purchase and distribution of the Offered Shares by the Underwriter and the listing of

the Offered Shares on the Exchange, no consent, approval, authorization or order of, or filing, qualification or registration (each an

“Authorization”) with, any court, governmental or regulatory agency or body, foreign or domestic, which has not been

made, obtained or taken and is not in full force and effect, is required for the execution, delivery and performance of this Agreement

by the Company, the issuance and sale of the Offered Shares or the consummation of the transactions contemplated hereby; and no event

has occurred that allows or results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination

or invalidation of any such Authorization or any other impairment of the rights of the holder or maker of any such Authorization.

(xxvii)

Possession of Licenses and Permits. The Company and its Subsidiaries possess all such permits, licenses, sub-licenses, certificates,

approvals, clearances, exemptions, registrations, consents and other authorizations (collectively, “Governmental Licenses”)

issued by the appropriate Governmental Entities necessary to conduct the business now operated by them (including, without limitation,

all such Governmental Licenses required by the FDA, the U.S. Department of Agriculture, the Federal Trade Commission, and any other applicable

federal, state, local or foreign agencies or bodies engaged in the regulation of food safety, food manufacturing, labeling, distribution

or other activities related to the business now operated by the Company and its Subsidiaries), except where the failure so to possess

could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company and its Subsidiaries

are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply could not reasonably

be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company has fulfilled and performed all of its material

obligations with respect to the Governmental Licenses and, to the knowledge of the Company, no event has occurred which allows, or after

notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of the

Company as a holder of any permit, except where the failure to so fulfill or perform, or the occurrence of such event, could not reasonably

be expected, individually or in the aggregate, to have a Material Adverse Effect. All of the Governmental Licenses are valid and in full

force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full

force and effect could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Neither the Company

nor its Subsidiaries has received any notice of proceedings relating to the revocation, suspension, termination, invalidation or modification

of, or non-compliance with, any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling

or finding, would result in a Material Adverse Effect. The manufacturing facilities and operations of its suppliers are operated in compliance

in all material respects with all Applicable Laws (as defined below) and Governmental Licenses.

(xxviii)

Title to Property. The Company and its Subsidiaries have good and marketable title to all real property owned by them and

good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims,

restrictions or encumbrances of any kind; and all of the leases and subleases material to the business of the Company and its Subsidiaries,

considered as one enterprise, and under which the Company or its Subsidiaries holds properties described in the Registration Statement,

the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such Subsidiary has any

notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under

any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued

possession of the leased or subleased premises under any such lease or sublease.

(xxix)

Title to Intellectual Property. The Company owns or has valid, binding and enforceable licenses or other rights under the

patents, patent applications, licenses, inventions, copyrights, know how (including trade secrets and other proprietary or confidential

information, systems or procedures), trademarks, service marks, trade names or other intellectual property necessary for, or used in the

conduct, or the proposed conduct, of the business of the Company in the manner described in the Registration Statement, the General Disclosure

Package and the Prospectus (collectively, the “Intellectual Property”); the patents, trademarks, and copyrights, if

any, included within the Intellectual Property are valid, enforceable, and subsisting; (A) the Company is not obligated to pay a material

royalty, grant a license to, or provide other material consideration to any third party in connection with the Intellectual Property,

(B) the Company has not received any notice of any claim of infringement, misappropriation or conflict with any asserted rights of others

with respect to any of the Company’s products, services, processes or Intellectual Property, (C) to the knowledge of the Company,

neither the sale nor use of any of the discoveries, inventions, products, services or processes of the Company referred to in the Registration

Statement, the General Disclosure Package or the Prospectus do or will infringe, misappropriate or violate any right or valid patent claim

of any third party, (D) none of the technology employed by the Company has been obtained or is being used by the Company in material violation

of any contractual obligation binding on the Company or, to the Company’s knowledge, upon any of its officers, directors or employees

or otherwise in violation of the rights of any persons, (E) to the knowledge of the Company, no third party has any ownership right in

or to any Intellectual Property that is owned by the Company, other than any co-owner of any patent or patent application in the Intellectual

Property who is listed as co-owner in the records of the U.S. Patent and Trademark Office (the “USPTO”), and no third

party has any ownership right in or to any Intellectual Property in any field of use that is exclusively licensed to the Company, other

than any licensor to the Company of such Intellectual Property, (F) there is no material infringement by third parties of any Intellectual

Property, (G) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging

the Company’s rights in or to any Intellectual Property, (H) there is no pending or, to the Company’s knowledge, threatened

action, suit, proceeding or claim by others challenging the validity or scope of any Intellectual Property, and (I) all Intellectual Property

owned by or exclusively licensed to the Company or its Subsidiaries is free and clear of all liens, encumbrances, defects or other restrictions

(other than non-exclusive licenses granted in the ordinary course of business), except those that could not be reasonably expected, individually

or in the aggregate, to have a Material Adverse Effect. The Company is in compliance with the terms of each agreement pursuant to which

Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect.

(xxx)

Compliance with ERISA. The Company and any “employee benefit plan” (as defined under the Employee Retirement

Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”))

established or maintained by the Company, or its “ERISA Affiliates” (as defined below) are in compliance in all material respects

with ERISA. “ERISA Affiliates” means, with respect to the Company, any member of any group of organizations described

in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations

thereunder (the “Code”) of which the Company is a member. No “reportable event” (as defined under ERISA)

has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the

Company, or any of its ERISA Affiliates. No “employee benefit plan” established or maintained by the Company or any of its

ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities”

(as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any liability

under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections

412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan” established or maintained by the Company or any of its

ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by

action or failure to act, which would cause the loss of such qualification.

(xxxi)

Non-Competition; Non-Solicitation. No director or officer of the Company or any of its Subsidiaries is subject to any non-competition

agreement or non-solicitation agreement with any employer or prior employer which could materially affect such director’s or officer’s

ability to serve and act in the capacity of a director or officer of the Company or a Subsidiary, as the case may be.

(xxxii)

Environmental Laws. (A) Neither the Company nor any Subsidiary is in material violation of any applicable federal, state,

local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation

thereof, including any judicial or administrative order, consent, decree or judgment, relating to protection of human health, the environment

(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) natural resources or wildlife,

from exposure to or the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,

including per- and polyfluoroalkyl substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, “Hazardous

Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous

Materials (collectively, “Environmental Laws”), (B) the Company and its Subsidiaries have all permits, authorizations

and approvals required under any applicable Environmental Laws and are each in material compliance with their requirements, (C) there

are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits, demands, demand

letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against

the Company or any Subsidiary and (D) there are no events or circumstances that would reasonably be expected to form the basis of a governmental

order for remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company

or any Subsidiary relating to Hazardous Materials or any Environmental Laws.

(xxxiii)

Accounting Controls and Disclosure Controls. The Company and each of its Subsidiaries maintain effective internal control

over financial reporting (as defined under Rule -13a-15 and 15d--15 under the Exchange Act Regulations) and a system of internal accounting

controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general

or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity

with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general

or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals

and appropriate action is taken with respect to any differences. Since the end of the Company’s most recent fiscal year, there has

been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (2) no

change in the Company’s internal control over financial reporting that has materially adversely affected, or is reasonably likely

to materially adversely affect, the Company’s internal control over financial reporting. The Company and each of its Subsidiaries

maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the Exchange Act Regulations)

that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the

Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms,

and is accumulated and communicated to the Company’s management, including its principal executive officer or officers and principal

financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.

(xxxiv)

Payment of Taxes. All United States federal income tax returns of the Company and its Subsidiaries required by law to be

filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments

against which appeals have been or will be promptly taken and as to which adequate reserves have been provided in conformity with GAAP.

The United States federal income tax returns of the Company through the fiscal year ended December 31, 2025 have been settled and no assessment

in connection therewith has been made against the Company. The Company and its Subsidiaries have filed all other tax returns that are

required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such

returns could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and have paid all taxes

due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes, if any,

as are being contested in good faith and as to which adequate reserves have been established by the Company. The charges, accruals and

reserves on the books of the Company in respect of any income and corporation tax liability, including all federal, state and foreign

income and franchise taxes, for any years not finally determined are, in conformity with GAAP, adequate to meet any assessments or re-assessments

for additional income tax for any years not finally determined, except to the extent of any inadequacy that could not reasonably be expected,

individually or in the aggregate, to have a Material Adverse Effect.

(xxxv)

Transfer Tax. There are no transfer taxes or other similar fees or charges under federal law, the laws of any state, any

foreign law, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement

or the issuance or sale by the Company of the Offered Shares.

(xxxvi)

Insurance. The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and

reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged in the

same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or its Subsidiaries

will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage

from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not reasonably

be expected, individually or in the aggregate, to have a Material Adverse Effect. Neither the Company nor its Subsidiaries has been denied

any insurance coverage which it has sought or for which it has applied.

(xxxvii) Investment

Company Act. The Company is not required, and upon the issuance and sale of the Offered Shares as herein contemplated and the application

of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be

required, to register as an “investment company” under the Investment Company Act of 1940, as amended.

(xxxviii) Absence

of Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly

or indirectly, any action which is designed, or would be expected, to cause or result in, or which otherwise constitutes, the stabilization

or manipulation of the price of any security of the Company to facilitate the sale or resale of the Offered Shares or to result in a

violation of Regulation M under the Exchange Act.

(xxxix)

Anti-Bribery Laws. None of the Company, any of its Subsidiaries, or, to the knowledge of the Company, any of their respective

directors, officers, agents, employees or affiliates, has taken or will take any action in furtherance of an offer, payment, promise

to pay, or authorization or approval of the unlawful payment or giving of money, property, gifts or anything else of value, directly

or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled

entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing,

or any political party or party official or candidate for political office) to influence official action or secure an improper advantage

for the Company; and the Company, each of its Subsidiaries and, to the Company’s knowledge, each of their respective affiliates

acting in such capacity, have conducted their businesses in compliance with applicable anti-corruption laws. The Company will not directly

or indirectly use the proceeds of the sale of the Offered Shares, or lend, contribute or otherwise make available such proceeds in any

other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter,

advisor, investor or otherwise) of applicable anti-corruption laws.

(xl)

Anti-Corruption Laws. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer,

agent, employee, affiliate or other person acting on behalf of the Company or its Subsidiaries is aware of or has taken any action, directly

or indirectly, that would result in a violation by such persons in connection with their activities on behalf of the Company of the Foreign

Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), the UK Bribery Act

2010 and any other applicable anti-corruption law (collectively, the “Anti-Corruption Laws”). Each of the Company,

its Subsidiaries and, to the best of the Company’s knowledge, any director, officer, agent, employee, affiliate or other person

acting on behalf of the Company or any of its Subsidiaries or affiliates has conducted its respective business in compliance with the

Anti-Corruption Laws and is not aware of any action that would be in violation of Anti-Corruption Laws, including, without limitation,

making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise

to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything

of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof

or any candidate for foreign political office, in contravention of the Anti-Corruption Laws; and the Company, its Subsidiaries and, to

the knowledge of the Company, its affiliates have conducted their businesses in compliance with the Anti-Corruption Laws and have instituted

and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance

therewith. The Company will not directly or indirectly use the proceeds of the sale of the Offered Shares, or lend, contribute or otherwise

make available such proceeds in any other manner that will result in a violation by any Person (including any Person participating in

the transaction, whether as underwriter, advisor, investor or otherwise) of the Anti-Corruption Laws.

(xli)

Anti-Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times

in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act

of 1970, as amended, applicable provisions of the USA Patriot Act of 2001, the Money Laundering Control Act of 1986, the Anti-Money Laundering

Act of 2020, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar

rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Anti-Money

Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or its Subsidiaries

with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(xlii)

OFAC. None of the Company, its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee,

affiliate or representative of the Company or its Subsidiaries is an individual or entity (“Person”) currently the

subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department

of the Treasury’s Office of Foreign Assets Control and the U.S. Department of State, the United Nations Security Council, the European

Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the

Company located, organized or resident in a country or territory that is the subject of Sanctions, including, without limitation, the

so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, the Crimea Region of Ukraine, the non-government

controlled areas of the Zaporizhzhia and Kherson Regions, Cuba, Iran, North Korea and Syria; and the Company will not directly or indirectly

use the proceeds of the sale of the Offered Shares, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint

venture partners or other Person, to fund or facilitate any activities of or business with any Person, or in any country or territory,

that, at the time of such funding or facilitation, is the subject of Sanctions or in any other manner that will result in a violation

by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.

For the past five years, the Company and its Subsidiaries have not engaged in and are not now engaged in any dealings or transactions

with any person or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

(xliii)

Outbound Investments. Neither the Company nor any of its subsidiaries is a “covered foreign person,” as that

term is defined in 31 C.F.R. § 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage,

directly or indirectly, in a “covered activity” or “covered transaction,” as such terms are defined in 31 C.F.R.

§ 850.208 and 31 C.F.R. § 850.209, respectively, any other activity that would cause the Underwriters to be in violation of

the Outbound Investment Rules or cause the Underwriters to be legally prohibited by the Outbound Investment Rules from performing

under this Agreement (“Covered Activity”).  Neither the Company nor any of its subsidiaries is a “covered

foreign person,” as that term is defined in 31 C.F.R. § 850.209. The Company does not have any joint ventures that engages

in or plans to engage in any Covered Activity. The Company also does not, directly or indirectly, hold a board seat on, have a voting

or equity interest in, or have any contractual power to direct or cause the direction of the management or policies of any person or persons

that engages or plans to engage in any Covered Activity. For the purpose of this Agreement, “Outbound Investment Rules” means

the regulations administered and enforced, together with any related public guidance issued, by the United States Treasury Department

under U.S. Executive Order 14105 of August 9, 2023, or any similar law or regulation as of the date of this Agreement, and as codified

at 31 C.F.R. §850.101 et seq.

(xliv)

Lending Relationship. The Company does not have any material lending or other relationship with any banking

or lending affiliate of any Underwriter.

(xlv)

No Bankruptcy Proceeding. The Company is not in or subject to a bankruptcy or insolvency proceeding in any jurisdiction.

(xlvi)

Maintenance of Rating. The Company has no debt securities or preferred stock that is rated by any “nationally recognized

statistical rating organization” (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Securities

Act).

(xlvii)

Privacy and Data Protection. The Company and its Subsidiaries have at all times protected and maintained the confidentiality

and integrity of all personal information, protected health information, consumer information and any other confidential or proprietary

information of the Company, its Subsidiaries or any third parties in its possession or under its control (collectively, “Company

Data”). The Company and its Subsidiaries have been in compliance in all material respects with all privacy, data security and

data protection laws, rules, and regulations applicable to the Company’s collection, use, processing, transfer, protection, disposal,

disclosure, handling, storage and analysis of Company Data, including any internal- or external-facing policies and procedures or contractual

obligations related thereto (collectively, “Data Protection Requirements”). The Company has provided all requisite

notices and obtained any required consents, and satisfied any other requirements necessary for the lawful processing of Company Data as

currently conducted and in relation to the consummation of the proposed transaction. The Company and its Subsidiaries have implemented

and maintain reasonable and appropriate administrative, technical, and physical measures consistent with the state of the art for the

industry in which the Company operates to comply with Data Protection Requirements. The tangible and digital information technology systems

(including computers, devices, mobile services, screens, servers, workstations, routers, hubs, switches, networks, data communications

lines, technical data, equipment and hardware), software and telecommunications systems used or held for use by the Company and its Subsidiaries

(the “Company IT Assets”) are adequate and operate, in accordance with their documentation and functional specifications

to support the business of the Company and its Subsidiaries, now and as envisaged in the Registration Statement, the General Disclosure

Package and the Prospectus. To the Company’s knowledge, no Company IT Assets contain any virus, “time bomb”, “back

door”, “trap door”, Trojan horse, spyware, keylogger software, worm or other software routines, faults, malicious code,

damaging devices, or hardware components designed to permit misuse of Company IT Assets or any data thereon. The Company and its Subsidiaries

have established and maintain a commercially reasonable, written program to protect Company Data against unauthorized access, use, disclosure,

deletion, destruction, or alteration. The Company and its Subsidiaries have established commercially reasonable disaster recovery and

security plans, procedures and facilities for the business consistent with industry standards and practices in all material respects,

including, without limitation, for the Company IT Assets and Company Data. For the past five (5) years, the Company and its Subsidiaries

have not suffered or incurred any actual or reasonably suspected security breach, compromise or other incident resulting in the unauthorized

access, acquisition, interruption, alteration, modification, loss, theft, corruption or use of any Company IT Asset or Company Data (“Security

Incident”), except where such Security Incident could not reasonably be expected, individually or in the aggregate, to result

in a Material Adverse Effect. The Company and its Subsidiaries have not been required to notify (nor voluntarily notified) any individual

or governmental authority of any Security Incident, and there is not currently, nor has there ever been, any pending or threatened action,

proceeding, investigation, suit or claim against the Company with respect to the Company’s compliance with Data Protection Requirements

or its processing of Company Data.

(xlviii)

No Broker Fees. There are no contracts, agreements or understandings between the Company and any person that would give

rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or other like payment in connection

with the offering of the Offered Shares contemplated hereby other than pursuant to this Agreement.

(xlix)

Forward-Looking Statement. Each financial or operational projection or other “forward-looking statement” (as

defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the General

Disclosure Package and the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration

by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) as required, is accompanied

by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such

forward-looking statement. No such statement was made with the knowledge of a director or senior manager of the Company that was false

or misleading.

(l)

Statistical and Market-Related Data. Any statistical, industry-related and market-related data included or incorporated

by reference in the Registration Statement, the General Disclosure Package or the Prospectus were obtained or derived from sources that

the Company, reasonably and in good faith believes are reliable and accurate, such data are consistent with the sources from which they

are derived, and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.

(b)

Representations and Warranties of the Selling Stockholder. The Selling Stockholder represents, warrants and covenants to

the Underwriter as of the date hereof, the Applicable Time and the Closing Time (as defined below)and agrees with the Underwriter, as

follows:

(i)

Organization and Good Standing. The Selling Stockholder has been duly organized and is validly existing and in good standing as

a public benefit corporation under the laws of the State of Delaware.

(ii)

The Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by or on behalf of the Selling

Stockholder.

(iii)

Title to Offered Shares to be Sold. The Selling Stockholder has, and on the Closing Time will have, good and valid title

to all of the Offered Shares subject to sale by the Selling Stockholder pursuant to this Agreement on such date and the legal right and

power to sell, transfer and deliver all of the Offered Shares which may be sold by the Selling Stockholder pursuant to this Agreement

and to comply with its other obligations hereunder.

(iv)

Delivery of the Offered Shares to be Sold. Delivery of Offered Shares by the Selling Stockholder pursuant to this Agreement

will pass good and valid title to, or a valid “security entitlement” within the meaning of Section 8-501 of

the New York Uniform Commercial Code (the “UCC”) to, such Offered Shares, free and clear of any security interest,

mortgage, pledge, lien, encumbrance or other adverse claim. Upon payment for the Offered Shares to be sold by the Selling Stockholder

pursuant to this Agreement, delivery of such Offered Shares, as directed by the Representative, to Cede & Co. (“Cede”)

or such other nominee as may be designated by the Depository Trust Company (“DTC”), registration of such Offered Shares

in the name of Cede or such other nominee and the crediting of such Offered Shares on the books of DTC to securities accounts of the Underwriter

(assuming that neither DTC nor the Underwriter has notice of any adverse claim (within the meaning of Section 8-105 of the UCC) to such

Offered Shares), (A) in the case of Offered Shares delivered in certificated or uncertificated form, DTC shall be a “protected purchaser”

of such Offered Shares within the meaning of Section 8-303 of the UCC, (B) in the case of delivery in the form of security entitlements,

under Section 8-501 of the UCC, the Underwriter will acquire a valid security entitlement in respect of such Offered Shares and (C) in

the case of delivery in the form of security entitlements, no action based on any “adverse claim”, within the meaning of Section

8-102 of the UCC, to such Offered Shares may be asserted against the Underwriter with respect to such security entitlement; for purposes

of this representation, the Selling Stockholder may assume that when such payment, delivery and crediting occur, (1) such Offered Shares

will have been registered in the name of Cede or another nominee designated by DTC, in each case on the Company’s share registry

in accordance with its certificate of incorporation, bylaws and applicable law, (2) DTC will be a “clearing corporation” within

the meaning of Section 8-102 of the UCC and (3) appropriate entries to the accounts of the Underwriter on the records of DTC will have

been made pursuant to the UCC.

(v)

Non-Contravention; No Further Authorizations or Approvals Required. Except (a) as will have been obtained on or prior to

the Closing Time, (b) as may be required under foreign or state securities or blue sky laws or by the FINRA or by the Exchange, and (c)

as would not impair in any material respect the ability of the Selling Stockholder to consummate its obligations hereunder, the execution

and delivery by the Selling Stockholder of, and the performance by the Selling Stockholder of its obligations under, this Agreement will

not contravene or conflict with, result in a breach of, or constitute a breach or default under, or require the consent of any other party

to, the charter or by-laws or other organizational documents of the Selling Stockholder or any other agreement or instrument to which

the Selling Stockholder is a party or by which it is bound or under which it is entitled to any right or benefit, any provision of applicable

law or any judgment, order, decree or regulation applicable to the Selling Stockholder of any court, regulatory body, administrative agency,

governmental body or arbitrator having jurisdiction over the Selling Stockholder. No consent, approval, authorization or other order of,

or registration or filing with, any court or other governmental authority or agency, is required for the consummation by the Selling Stockholder

of the transactions contemplated in this Agreement, except such as may be required under the Securities Act, applicable state securities

or blue sky laws and from the FINRA, or as would not impair in any material respect the ability of the Selling Stockholder to consummate

its obligations hereunder.

(vi)

No Registration, Pre-emptive, Co-Sale or Other Similar Rights. The Selling Stockholder: (A) does not have any registration

or other similar rights to have any securities registered for sale by the Company under the Registration Statement or included in the

offering contemplated by this Agreement, except for such rights as are described in the Registration Statement, the General Disclosure

Package and the Prospectus under “Selling Stockholder;” (B) does not have any preemptive right, co-sale right, right of first

refusal or other similar right to purchase any of the Offered Shares that are to be sold by the Company or any of the other Selling Stockholders

to the Underwriter pursuant to this Agreement, except for such rights as the Selling Stockholder has waived prior to the date hereof and

are described in the Registration Statement, the General Disclosure Package and the Prospectus; and (C) does not own any warrants, options

or similar rights to acquire, and does not have any right or arrangement to acquire, any capital stock, right, warrants, options or other

securities from the Company, in each case, other than those described, or incorporated by reference in, the Registration Statement, the

General Disclosure Package and the Prospectus.

(vii)

No Further Consents, etc. Except for such consents, approvals and waivers as have been obtained by the Selling Stockholder

on or prior to the date of this Agreement, no consent, approval or waiver is required under any instrument or agreement to which the Selling

Stockholder is a party or by which it is bound or under which it is entitled to any right or benefit, in connection with the offering,

sale or purchase by the Underwriter of any of the Offered Shares which may be sold by the Selling Stockholder under this Agreement or

the consummation by the Selling Stockholder of any of the other transactions contemplated hereby.

(viii)

Disclosure Made by the Selling Stockholder in the Prospectus. All information furnished to the Company or the Underwriter

by or on behalf of the Selling Stockholder in writing expressly for use in the Registration Statement and the Prospectus is, and on the

Closing Time will be, true, correct, and complete in all material respects, and did not, as of the Applicable Time, and on the Closing

Time and the Date of Delivery will not, contain any untrue statement of a material fact or omit to state any material fact necessary

to make such information not misleading, it being understood and agreed that for purposes of this Agreement, the only information furnished

by the Selling Stockholder (the “Selling Stockholder Information”) consists of the number of offered shares and the

address and other information (excluding percentages) with respect to the Selling Stockholder which appears in the Preliminary Prospectus

and the Prospectus in the table (and corresponding footnotes) under the caption “Selling Stockholder.”

(x)

No Price Stabilization or Manipulation; Compliance with Regulation M. The Selling Stockholder has not taken, directly or

indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered Shares or

any reference security, whether to facilitate the sale or resale of the Offered Shares or otherwise, and has taken no action which would

directly or indirectly violate any provision of Regulation M.

(xi)

Distribution of Offering Materials by the Selling Stockholder. Prior to the completion of the Underwriter’s distribution

of the Offered Shares, the Selling Stockholder has not distributed and will not distribute any offering material in connection with the

offering and sale of the Offered Shares other than the Registration Statement, the General Disclosure Package and the Prospectus.

(xiii)

Sanctions. The Selling Stockholder is not currently the subject or the target of Sanctions and will not directly or indirectly

use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture

partner or other person or entity, for the purpose of financing the activities of any person that at the time of such financing, is the

subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating

in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Selling

Stockholder and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with

any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any country or territory

that is the subject of Sanctions.

(xiv)

Anti-Corruption Laws. The operations of such Selling Stockholder and each of

its subsidiaries are conducted in material compliance with applicable Anti-Corruption Laws, and

no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Selling

Stockholder or any of its subsidiaries with respect to the Anti-Corruption Laws is pending or, to the knowledge of such Selling Stockholder,

threatened. Such Selling Stockholder will not use, directly or knowingly indirectly, the

proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything

else of value, to any person in violation of any applicable Anti-Corruption Laws.

(xv)

Anti-Money Laundering Laws. the operations of such Selling Stockholder and each of its subsidiaries are conducted in material

compliance with all applicable Anti-Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency,

authority or body or any arbitrator involving such Selling Stockholder or any of its subsidiaries with respect to the Anti-Money Laundering

Laws is pending or, to the knowledge of such Selling Stockholder, threatened.

(xvi)

ERISA. The Selling Stockholder is not (A) an employee benefit plan subject to Title I of ERISA, (B) a plan or account subject

to Section 4975 of the Code or (C) an entity deemed to hold “plan assets” of any such plan or account under Section 3(42)

of ERISA, 29 C.F.R. 2510.3-101, or otherwise.

(xvii)

No Association with FINRA. Neither the Selling Stockholder nor any of its affiliates directly, or indirectly through one

or more intermediaries, controls, or is controlled by, or is under common control with any member firm of FINRA or is a person associated

with a member (within the meaning of the FINRA By-Laws) of FINRA. None of the proceeds received by the Selling Stockholder from the sale

of the Offered Shares will be paid to a member of FINRA or any affiliate of such member participating in the transactions contemplated

by this Agreement.

Any certificate signed by the Selling Stockholder

and delivered to the Underwriter or to counsel for the Underwriter shall be deemed a representation and warranty by the Selling Stockholder

to the Underwriter as to the matters covered thereby.

The Selling Stockholder has a reasonable basis

for making each of the representations set forth in this Section 1(b). The Selling Stockholder acknowledges that the Underwriter and,

for purposes of the opinion to be delivered hereby, counsel to the Selling Stockholder and counsel to the Underwriter, will rely upon

the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.

(c)

Officer’s Certificates. Any certificate signed by any officer of the Company or any of its Subsidiaries delivered

to the Representative or to counsel for the Underwriter shall be deemed a representation and warranty by the Company to the Underwriter

as to the matters covered thereby.

SECTION 2.

Sale and Delivery to Underwriters; Closing.

(a)

Offered Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions

herein set forth, the Selling Stockholder agrees to sell to the Underwriter an aggregate of 3,454,756 Offered Shares. On the basis of

the representations, warranties and agreements herein contained, and upon the terms and conditions herein set forth, the Underwriter agrees

to purchase from the Selling Stockholder the number of Offered Shares set forth opposite its name on Schedule A. The purchase price

per Offered Share to be paid by the Underwriter to the Selling Stockholder shall be $18.425 per share.

(b)

Payment. Payment of the purchase price for the Offered Shares to be sold by the Selling Stockholder shall be made by wire

transfer in immediately available funds to the account specified by the Selling Stockholder, at the offices of White & Case LLP, or

at such other place as shall be agreed upon by the Representative and the Company, at 10:00 A.M. (New York City time) on May 19, 2026

(unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days after such

date as shall be agreed upon by the Representative and the Company (such time and date of payment and delivery being herein called “Closing

Time”). Delivery of the Offered Shares at the Closing Time shall be made through the facilities of The Depository Trust Company

unless the Representative shall otherwise instruct.

It is understood that the

Underwriter has authorized the Representative, for its account, to accept delivery of, receipt for, and make payment of the purchase price

for, the Offered Shares which it has agreed to purchase. BTIG, individually and not as representative of the Underwriters, may (but shall

not be obligated to) make payment of the purchase price for the Offered Shares to be purchased by any Underwriter whose funds have not

been received by the Closing Time, but such payment shall not relieve such Underwriter from its obligations hereunder.

SECTION 3.

Covenants of the Company and Selling Stockholder. The Company and the Selling Stockholder (to the extent specified below)

covenant with the Underwriter as follows:

(a)

Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the

requirements of Rule 430B, and will notify the Representative as soon as practicable, and confirm the notice in writing, (i) when any

post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have

been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment

to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein)

or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration

Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus,

or of the suspension of the qualification of the Offered Shares for offering or sale in any jurisdiction, or of the initiation or threatening

of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the

Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act. The Company

will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance

on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for

filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus.

The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order

is issued, to obtain the lifting thereof at the earliest possible moment.

(b)

Continued Compliance with Securities Laws. The Company will comply with the Securities Act, the Securities Act Regulations,

the Exchange Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Offered Shares as contemplated

in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus

relating to the Offered Shares is (or, but for the exception afforded by Rule 172 under the Securities Act Regulations (“Rule

172”), would be) required by the Securities Act to be delivered in connection with sales of the Offered Shares, any event shall

occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriter or for the Company,

to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material

fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend

or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the

case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the

statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend

the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply

with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the Representative notice

of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration

Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any

proposed filing or use, furnish the Representative with copies of any such amendment or supplement and (C) file with the Commission any

such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative

or counsel for the Underwriter shall object. The Company will furnish to the Underwriter such number of copies of such amendment or supplement

as the Underwriter may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange

Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representative notice of its

intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representative with copies of any

such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document

to which the Representative or counsel for the Underwriter shall reasonably object.

(c)

Delivery of Registration Statements. The Company has furnished or will deliver to the Representative and counsel for the

Underwriter, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits

filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and signed

copies of all consents and certificates of experts, and will also deliver to the Representative, without charge, a conformed copy of the

Registration Statement as originally filed and each amendment thereto (without exhibits) for the Underwriter. The copies of the Registration

Statement and each amendment thereto furnished to the Underwriter will be identical to the electronically transmitted copies thereof filed

with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S--T.

(d)

Delivery of Prospectuses. The Company has delivered to the Underwriter, without charge, as many copies of each preliminary

prospectus as the Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by

the Securities Act. The Company will furnish to the Underwriter, without charge, during the period when a prospectus relating to the Offered

Shares is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of

copies of the Prospectus (as amended or supplemented) as the Underwriter may reasonably request. The Prospectus and any amendments or

supplements thereto furnished to the Underwriter will be identical to the electronically transmitted copies thereof filed with the Commission

pursuant to EDGAR, except to the extent permitted by Regulation S--T.

(e)

Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Underwriter, to qualify the Offered

Shares for offering and sale under (or obtain exemptions from the application of) the applicable securities laws of such states and other

jurisdictions (domestic or foreign) as the Representative may designate and to comply with such laws and maintain such qualifications,

registrations and exemptions in effect so long as required to complete the distribution of the Offered Shares; provided, however, that

the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer

in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any

jurisdiction in which it is not otherwise so subject. The Company will advise the Representative promptly of the suspension of the qualification

or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation

or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration

or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.

(f)

Rule 158. The Company will timely file such reports pursuant to the Exchange Act as are necessary in order to make generally

available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the

benefits contemplated by, the last paragraph of Section 11(a) of the Securities Act.

(g)

Listing. The Company will use its best efforts to effect and maintain the listing of the Common Shares (including the Offered

Shares) on the Exchange.

(h)

Restriction on Sale of Common Shares. During a period of 60 days from and including the date of the Prospectus, the Company

will not, without the prior written consent of the Representative (which consent may be withheld in its sole discretion), (i) directly

or indirectly, offer, pledge, lend, sell, contract to sell or lend, sell any option or contract to purchase, purchase any option or contract

to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any Common Shares or any securities convertible

into or exercisable or exchangeable for Common Shares or file or confidentially submit any registration statement under the Securities

Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole

or in part, directly or indirectly, the economic consequence of ownership of the Common Shares, whether any such swap or transaction described

in clause (i) or (ii) above is to be settled by delivery of Common Shares or such other securities, in cash or otherwise, or (iii) publicly

announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and (ii). The foregoing sentence

shall not apply to (A) the Offered Shares to be sold hereunder; (B) any Common Shares issued by the Company upon the exercise of an option

or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the

General Disclosure Package and the Prospectus; (C) grants, or settlement in Common Stock, of stock options, stock awards, restricted stock,

restricted stock units, performance units, or other equity awards and the issuance of Common Shares in settlement of any such existing

award granted under employee benefit plans, including any inducement awards, of the Company referred to in the Registration Statement,

the General Disclosure Package and the Prospectus; (D) any Common Shares issued pursuant to any existing non-employee director stock plan

or deferral plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus;

or (E) the filing by the Company of any registration statement on Form S-8 or a successor form thereto.

(i)

Reporting Requirements. The Company, during the period when a Prospectus relating to the Offered Shares is (or, but for

the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be

filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.

Additionally, the Company shall report the use of proceeds from the issuance of the Offered Shares as may be required under Rule 463 under

the Securities Act.

(j)

Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative,

it will not make any offer relating to the Offered Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise

constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained

by the Company under Rule 433; provided that the Representative will be deemed to have consented to the Issuer Free Writing Prospectuses

listed on Schedule B-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i)

that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing

prospectus consented to, or deemed consented to, by the Representative as an “issuer free writing prospectus,” as defined

in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely

filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus

there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict

with the information contained in the Registration Statement which has not been superseded or modified, any preliminary prospectus or

the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company

will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus

to eliminate or correct such conflict, untrue statement or omission; provided, however, that prior to amending or supplementing any such

Issuer Free Writing Prospectus, the Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed

time of filing or use thereof, a copy of such proposed amended or supplemented Issuer Free Writing Prospectus, and the Company shall not

file, use or refer to any such amended or supplemented Issuer Free Writing Prospectus without the Representative’s prior written

consent.

(k)

Filing of Underwriter Free Writing Prospectuses. The Company shall not take any action that would result in an Underwriter

or the Company being required to file with the Commission pursuant to Rule 433(d) a free writing prospectus prepared by or on behalf of

such Underwriter that such Underwriter otherwise would not have been required to file thereunder.

(l)

Testing-the-Waters Materials. If at any time following the distribution of any Written Testing-the-Waters Communication

there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would

include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements

therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative

and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such

untrue statement or omission.

(m)

No Stabilization or Manipulation; Compliance with Regulation M. The Selling Stockholder will not take, directly or indirectly,

any action designed to or that might cause or result in stabilization or manipulation of the price of the Offered Shares or any reference

security with respect to the Offered Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Selling

Stockholder will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.

(n)

Notification. The Selling Stockholder will advise the Representative promptly, and if requested by the Representative, will

confirm such advice in writing, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to

be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), of (i) any Material

Adverse Effect, (ii) any change in information in the Registration Statement, any preliminary prospectus, any free writing prospectus,

the Prospectus or any amendment or supplement thereto relating to the Selling Stockholder, or (iii) any new material information

relating to the Company or relating to any matter stated in the Registration Statement, the General Disclosure Package or the Prospectus

that comes to the attention of the Selling Stockholder.

(o)

Delivery of Form W-9. To deliver to the Representative prior to the Closing Time a properly completed and executed United

States Treasury Department Form W-9.

SECTION 4.

Payment of Expenses.

(a)

Expenses. The Company agrees to pay or cause to be paid all expenses incident to the performance of its obligations under

this Agreement, including, (i) the preparation, printing and filing of the Registration Statement (including financial statements and

exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriter of copies

of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any

costs associated with electronic delivery of any of the foregoing by the Underwriter to investors, (iii) the preparation, issuance and

delivery of the certificates or security entitlements for the Offered Shares to the Underwriter, including any stock or other transfer

taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Offered Shares to the Underwriter, (iv) the

fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the qualification or registration (or

exemption from the qualification or registration) of the Offered Shares under securities laws in accordance with the provisions of Section 3(e)

hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriter in connection therewith and in

connection with the preparation of a “Blue Sky Survey” and any supplement thereto, (vi) the fees and expenses of any transfer

agent or registrar for the Offered Shares, (vii) the costs and expenses of the Company relating to investor presentations on any “road

show” undertaken in connection with the marketing of the Offered Shares, including without limitation, expenses associated with

the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations,

travel and lodging expenses of the representatives and officers of the Company and any such consultants, and the cost of aircraft and

other transportation chartered in connection with the road show, (viii) the filing fees incident to, and the reasonable fees and disbursements

of counsel to the Underwriter in connection with, the review by FINRA of the terms of the sale of the Offered Shares (such reimbursement,

together with the reimbursements set forth in (v) above, not to exceed $15,000), (ix) the fees and expenses incurred in connection with

the listing of the Offered Shares on the Exchange, and (x) the costs and expenses (including, without limitation, any damages or other

amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Offered

Shares made by the Underwriter caused by a breach of the representation contained in the third sentence of Section 1(a)(ii).

The Selling Stockholder further agrees with the

Underwriter to pay (directly or by reimbursement) all fees and expenses incident to the performance of its obligations under this Agreement

that are not otherwise specifically provided for herein, including but not limited to (i) fees and expenses of counsel for the Selling

Stockholder, and (ii) expenses and taxes incident to the sale and delivery of the Offered Shares to be sold by the Selling Stockholder

to the Underwriter hereunder; provided, it is understood and agreed that the Company shall bear, and the Selling Stockholder shall not

be required to pay or to reimburse the Company for, the cost of any other matters not directly relating to the sale and purchase of the

Shares pursuant to this Agreement.

(b)

Termination of Agreement. If this Agreement is terminated by the Representative in accordance with the provisions of Section 5,

Section 9 or Section 10 hereof, the Company shall reimburse the Underwriter for all of their reasonably documented out--of--pocket

expenses, including the fees and disbursements of counsel for the Underwriter.

SECTION 5.

Conditions of Underwriters’ Obligations. The obligations of the Underwriter hereunder are subject to the accuracy

of the representations and warranties of the Company and the Selling Stockholder contained herein or in certificates of any officer of

the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company and the Selling

Stockholder of their respective covenants and other obligations hereunder, and to the following further conditions:

(a)

Effectiveness of Registration Statement. The Registration Statement has become effective and, at the Closing Time, no stop

order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the Securities

Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for

any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; the Prospectus and each

Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free

Writing Prospectus, to the extent required by Rule 433); and the Company has complied with each request (if any) from the Commission for

additional information to the reasonable satisfaction of counsel to the Underwriter.

(b)

Opinion of Counsel for Company. At the Closing Time, the Representative shall have received the opinion and the negative

assurance letter, each dated the Closing Time, of Kelley Drye & Warren LLP, counsel for the Company, dated as of such date, and substance

reasonably satisfactory to the Representative.

(c)

Opinion of Counsel for Underwriters. At the Closing Time, the Representative shall have received the opinion and negative

assurance letter, each dated the Closing Time, of White & Case LLP, counsel for the Underwriter, together with signed or reproduced

copies of such letters for the Underwriter in form and substance satisfactory to the Representative.

(d)

Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective

dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse

change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries

considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a

certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing

Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties of the Company

in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii) the

Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing

Time, and (iv) no stop order suspending the effectiveness of the Registration Statement under the Securities Act has been issued,

no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of

those purposes have been instituted or are pending or, to their knowledge, contemplated.

(e)

Accountant’s Comfort Letter. At the time of the execution of this Agreement, the Representative shall have received

from Grant Thornton LLP a letter, dated such date, in form and substance satisfactory to the Representative, together with signed or reproduced

copies of such letter for the Underwriter containing statements and information of the type ordinarily included in accountants’

“comfort letters” to underwriters with respect to the financial statements and certain financial information contained in

the Registration Statement, the General Disclosure Package and the Prospectus.

(f)

Bring-down Comfort Letter. At the Closing Time, the Representative shall have received from Grant Thornton LLP a letter,

dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e)

of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.

(g)

Opinion of Counsel for the Selling Stockholder. At the Closing Time, the Representative shall have received the opinion

of Wachtell, Lipton, Rosen and Katz, counsel for the Selling Stockholder, dated as of such date, and substance reasonably satisfactory

to the Representative.

(h)

Selling Stockholder’s Certificate. At the Closing Time, the Representative shall receive a written certificate of

the Selling Stockholder, dated as of such date, to the effect that:

(i)

the representations, warranties and covenants of the Selling Stockholder set forth in ‎Section 1(b) of this Agreement are true

and correct with the same force and effect as though expressly made by the Selling Stockholder on and as of such date; and

(ii)

such Selling Stockholder has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied

at or prior to such date in all material respects.

(i)

Approval of Listing. At the Closing Time, the Offered Shares shall have been approved for listing on the Exchange.

(j)

No Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of

the underwriting terms and arrangements relating to the offering of the Offered Shares.

(k)

Lock-up Agreements. At the date of this Agreement, the Representative shall have received an agreement substantially in

the form of Exhibit A hereto signed by all of the Company’s directors and executive officers.

(l)

No Rating. Neither the Company nor its Subsidiaries have any debt securities or preferred stock that are rated by any “nationally

recognized statistical rating agency” (as defined in Section 3(a)(62) of the 1934 Act).

(m)

Additional Documents. At the Closing Time, counsel for the Underwriter shall have been furnished with such other documents

and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Offered Shares

as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of

the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Offered Shares

as herein contemplated shall be reasonably satisfactory in form and substance to the Representative and counsel for the Underwriter.

(n)

Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required

to be fulfilled, this Agreement may be terminated by the Representative by notice to the Company or the Selling Stockholder at any time

at or prior to Closing Time, and such termination shall be without liability of any party to any other party except as provided in Section

4 and except that Sections 1, 4, 6, 7, 8, 13, 15, 16 and 17 shall survive any such termination and remain in full force and effect.

SECTION 6.

Indemnification.

(a)

Indemnification of Underwriters by the Company. The Company agrees to indemnify and hold harmless the Underwriter, its affiliates

(as such term is defined in Rule 501(b) under the Securities Act (each, an “Affiliate”)), its directors, officers,

members, partners, employees and selling agents and each person, if any, who controls the Underwriter within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act as follows:

(i) against

any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue

statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be

a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or

necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material

fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the

General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided

to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares (“Marketing

Materials”), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically),

or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters

Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of

a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

(ii) against

any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement

of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever

based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section

6(e) below) any such settlement is effected with the written consent of the Company;

(iii) against

any and all expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel chosen by the Representative),

reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental

agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged

untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;

provided, however, that this

indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement

or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information

deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto)

in reliance upon and in conformity with the Underwriter Information.

(b)

Indemnification of Underwriter by Selling Stockholder. The Selling Stockholder agrees to indemnify and hold harmless the

Underwriter, its Affiliates, its directors, officers, members, partners, employees, its selling agents and each person, if any, who controls

the Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act as follows:

(i)

against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or

alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information

deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated

therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement

of a material fact included (A) in any Marketing Materials, including any roadshow or investor presentations made to investors by the

Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing

Prospectus, any Written Testing-the-Waters Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement

thereto) or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances

under which they were made, not misleading;

(ii) against

any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement

of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever

based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section

6(e) below) any such settlement is effected with the written consent of the Company;

(iii) against

any and all expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel chosen by the Representative),

reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental

agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged

untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;

provided, however, that this

indemnity agreement shall only apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement

or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information

deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto)

in reliance upon and in conformity with the Selling Stockholder Information.

(c)

Indemnification of Company, Selling Stockholder and their Respective Directors and Officers. The Underwriter severally agrees

to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and the Selling

Stockholder, and their respective directors and officers and each person, if any, who controls the Company or the Selling Stockholder,

as the case may be, within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all loss,

liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with

respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment

thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus

(or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.

(d)

Indemnification of Selling Stockholder by the Company. The Company agrees to indemnify and hold harmless the Selling Stockholder,

its Affiliates, and its and their directors, officers, members, partners, employees, and each person, if any, who controls the Selling

Stockholder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims,

damages or liabilities, joint or several, to which the Selling Stockholder may become subject, under the Securities Act or otherwise,

insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement

or alleged untrue statement of a material fact contained in the Registration Statement, the General Disclosure Package, any preliminary

prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, or the Prospectus, or any amendment or supplement

thereto, or in any Marketing Materials or arise out of or are based upon the omission or alleged omission to state therein a material

fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Selling Stockholder

for any documented legal or other expenses reasonably incurred by the Selling Stockholder in connection with investigating or defending

any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case loss,

claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission

made in the Registration Statement, the General Disclosure Package, any preliminary prospectus, any Issuer Free Writing Prospectus, any

Written Testing-the-Waters Communication, or the Prospectus, or any amendment or supplement thereto, or in any Marketing Materials, in

reliance upon and in conformity with Selling Stockholder Information or Underwriter Information.

(e)

Actions against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to

each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify

an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced

as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity

agreement. In the case of parties indemnified pursuant to Sections 6(a) and 6(b) above, counsel to the indemnified parties shall be selected

by the Representative, and, in the case of parties indemnified pursuant to Section 6(c) above, counsel to the indemnified parties shall

be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however,

that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified

party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition

to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar

or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall,

without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect

to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever

in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified

parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release

of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include

a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

(f)

Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying

party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for

any settlement of the nature contemplated by Sections 6(a)(ii) and 6(b)(ii) hereof effected without its written consent if (i) such settlement

is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall

have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying

party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

SECTION 7.

Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient

to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each

indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such

indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company or Selling

Stockholder, as applicable, on the one hand, and the Underwriter, on the other hand, from the offering of the Offered Shares pursuant

to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate

to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company or Selling Stockholder,

as applicable, on the one hand, and of the Underwriter, on the other hand, in connection with the statements or omissions which resulted

in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.

The relative benefits received

by Selling Stockholder, on the one hand, and the Underwriter, on the other hand, in connection with the offering of the Offered Shares

pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the

Offered Shares pursuant to this Agreement (before deducting expenses) received by the Selling Stockholder, on the one hand, and the total

underwriting discount received by the Underwriter, on the other hand, in each case as set forth on the cover of the Prospectus, bear to

the aggregate public offering price of the Offered Shares as set forth on the cover of the Prospectus.

The relative fault of the

Company or Selling Stockholder, as applicable, on the one hand, and the Underwriter, on the other hand, shall be determined by reference

to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state

a material fact relates to information supplied by the Company or Selling Stockholder, as applicable or by the Underwriter and the parties’

relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

The Company or Selling Stockholder

and the Underwriter agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata

allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this

Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to

above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating,

preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,

or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.

Notwithstanding the provisions

of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received

by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public.

No person guilty of fraudulent

misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was

not guilty of such fraudulent misrepresentation.

For purposes of this Section

7, each person, if any, who controls the Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange

Act and the Underwriter’s Affiliates, its directors, officers, members, partners, employees and selling agents shall have the same

rights to contribution as the Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement,

the Selling Stockholder and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section

20 of the Exchange Act shall have the same rights to contribution as the Company. The Underwriter’s obligations to contribute pursuant

to this Section 7 are several in proportion to the number of Offered Shares set forth opposite its name in Schedule A hereto

and not joint.

SECTION 8.

Representations, Warranties and Agreements to Survive. All representations, warranties, indemnities, rights of contribution,

agreements and other statements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted

pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of the Underwriter

or its Affiliates, its directors, officers, members, partners, employees or selling agents, any person controlling the Underwriter, its

officers or directors or any person controlling the Company and (ii) delivery of and payment for the Offered Shares.

SECTION 9.

Termination of Agreement.

(a)

Termination. The Representative may terminate this Agreement, by notice to the Company and the Selling Stockholder, at any

time at or prior to the Closing Time (i) if there has been, in the judgment of the Representative, since the time of execution of this

Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package

or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business

prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business,

(ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial

markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective

change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in

the judgment of the Representative, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts

for the sale of the Offered Shares, (iii) if trading in any securities of the Company has been suspended or materially limited by

the Commission or the Exchange, (iv) if trading generally on the New York Stock Exchange or in the exchanges operated by the Nasdaq Stock

Market LLC has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices

have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, (v) a material

disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream

or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.

(b)

Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any

party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall

survive such termination and remain in full force and effect.

SECTION 10.

Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time to purchase

the Offered Shares which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the

Representative shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters,

or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and

upon the terms herein set forth; if, however, the Representative shall not have completed such arrangements within such 24-hour period,

then:

(i)

if the number of Defaulted Securities does not exceed 10% of the number of Offered Shares to be purchased on such date, each of

the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions

that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or

(ii)

if the number of Defaulted Securities exceeds 10% of the number of Offered Shares to be purchased on such date, this Agreement

shall terminate without liability on the part of any non-defaulting Underwriter, except that Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall

survive such termination and remain in full force and effect.

No action taken pursuant to

this Section 10 shall relieve any defaulting Underwriter from liability in respect of its default.

In the event of any such default

which does not result in a termination of this Agreement, either the (i) Representative or (ii) the Selling Stockholder shall have the

right to postpone Closing Time for a period not exceeding seven days in order to effect any required changes in the Registration Statement,

the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter”

includes any person substituted for an Underwriter under this Section 10.

SECTION 11.

Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed

or transmitted by any standard form of telecommunication. Notices to the Underwriter shall be directed to BTIG, LLC at 65 East 55th

Street, New York, NY 10022, Attention: Michael Passaro, mpassaro@btig.com, with a copy to 65 East 55th Street, New York, NY 10022, Attention:

General Counsel (IBLegal@btig.com), with copies to White & Case LLP, 1221 Avenue of the Americas, New York, NY 10020, Attention: Drew

Valentine, Adam Johnson (drew.valentine@whitecase.com; adam.johnson@whitecase.com). Notices to the Company shall be directed to it at

6431 West Oakton St., Morton Grove, IL 60053, Attention: Secretary, with copies to Kelley Drye & Warren LLP, 333 West Wacker Drive,

26th Floor, Chicago, IL 60606, Attention: Timothy Lavender (tlavender@kelleydrye.com). Notices to the Selling Stockholder shall be directed

to Danone USA Public Benefit Corporation, 1 Maple Avenue, White Plains, NY 10605, Attention: Nancy Dowling (***@danone.com) and Danone

S.A., 59-61 rue La Fayette, 75009 Paris, France, Attention: Samantha Loh (***@danone.com), with copies to Wachtell Lipton Rosen &

Katz, 51 West 52nd Street, New York, NY 10019, Attention: Joshua R. Cammaker, Joseph S. Payne (jrcammaker@wlrk.com; jspayne@wlrk.com).

SECTION 12.

No Advisory or Fiduciary Relationship. The Company and the Selling Stockholder acknowledge and agree that (a) the purchase

and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares

and any related discounts and commissions, is an arm’s-length commercial transaction between them, on the one hand, and the Underwriter,

on the other hand, (b) in connection with the offering of the Offered Shares and the process leading thereto, the Underwriter is and has

been acting solely as a principal and is not the agent or fiduciary of the Company, the Selling Stockholder, any of its Subsidiaries or

their respective stockholders, creditors, employees or any other party, (c) the Underwriter has not assumed or will not assume an advisory

or fiduciary responsibility in favor of the Company with respect to the offering of the Offered Shares or the process leading thereto

(irrespective of whether the Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters)

and the Underwriter has no obligation to the Company with respect to the offering of the Offered Shares except the obligations expressly

set forth in this Agreement, (d) the Underwriter and its affiliates may be engaged in a broad range of transactions that involve interests

that differ from those of the Company and (e) the Underwriter has not provided any legal, accounting, regulatory or tax advice with respect

to the offering of the Offered Shares and the Company and the Selling Stockholder have consulted their own respective legal, accounting,

regulatory and tax advisors to the extent they deemed appropriate.

SECTION 13.

Recognition of the U.S. Special Resolution Regimes. In the event that any Underwriter that is a Covered Entity becomes subject

to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation

in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution

Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United

States.

In the event that any Underwriter

that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,

Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent

than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the

United States or a state of the United States.

For purposes of this Agreement,

(A) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance

with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that

term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is

defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined

in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that term

in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special

Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title

II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

SECTION 14.

Parties. This Agreement shall inure to the benefit of and be binding upon the Underwriter, the Company and the Selling Stockholder

and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person,

firm or corporation, other than the Underwriter, the Company and the Selling Stockholder and their respective successors and the controlling

persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable

right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and

provisions hereof are intended to be for the sole and exclusive benefit of the Underwriter, the Company and the Selling Stockholder and

their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for

the benefit of no other person, firm or corporation. No purchaser of Offered Shares from the Underwriter shall be deemed to be a successor

by reason merely of such purchase.

SECTION 15.

Waiver of Trial by Jury. The Company and the Selling Stockholder (on their behalf and, to the extent permitted by applicable

law, on behalf of their respective stockholders and affiliates) and the Underwriter hereby irrevocably waive, to the fullest extent permitted

by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions

contemplated hereby.

SECTION 16.

GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE

GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.

SECTION 17.

Consent to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement

or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America located in

the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County

of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the

exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such

jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document

by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought

in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other

proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any

such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

SECTION 18.

TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER

TO NEW YORK CITY TIME.

SECTION 19.

Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall

not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision

of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and

only such minor changes) as are necessary to make it valid and enforceable.

SECTION 20.

Counterparts. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by

any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute

one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by

the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable

law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly

delivered and be valid and effective for all purposes.

SECTION 21.

Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

SECTION

22. Entire Agreement; Amendment;

Waiver. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company, the Selling

Stockholder and the Underwriter, or any of them, with respect to the subject matter hereof. No amendment or waiver of any provision of

this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing

and signed by the parties hereto. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party.

No failure or delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or

partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.

SECTION 23.

General Provisions. Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately

represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions

of Section 6 and the contribution provisions of Section 7, and is fully informed regarding said provisions. Each of the parties hereto

further acknowledges that the provisions of Section 6 and Section 7 hereof fairly allocate the risks in light of the ability of the parties

to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration

Statement, any preliminary prospectus, the General Disclosure Package, each free writing prospectus and the Prospectus (and any amendments

and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.

[SIGNATURE PAGES FOLLOW]

If the foregoing is in accordance

with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along

with all counterparts, will become a binding agreement among the Underwriter, the Company and the Selling Stockholder in accordance with

its terms.

Very truly yours,

LIFEWAY FOODS, INC.

By: /s/ Julie Smolyansky

Name: Julie Smolyansky

Title: Chief Executive Officer

As Selling Stockholder

DANONE USA PUBLIC BENEFIT CORPORATION

By: /s/ Stéphane Gayet

Name: Stéphane Gayet

Title: Vice President of Finance and Chief Financial Officer

CONFIRMED AND ACCEPTED

As of the date first above written:

BTIG, LLC

By: /s/ Michael Passaro

Name: Michael Passaro

Title: Head of Capital Markets

For itself and as Representative of the Underwriters named in Schedule A

hereto.

[Signature Page to Underwriting

Agreement]

SCHEDULE A

Name of Underwriter

Number of

offered Shares

BTIG, LLC

3,454,756

Total

3,454,756

SCHEDULE B

Name of Selling Stockholder

Number of

Offered Shares

Danone USA Public Benefit Corporation

3,454,756

Total

3,454,756

SCHEDULE B-1

Pricing Terms

1. The

Selling Stockholder is selling 3,454,756 Common Shares.

2. The initial public offering

price per share for the Offered Shares shall be $19.50.

SCHEDULE B-2

Free Writing Prospectuses

None

SCHEDULE B-3

List of Written Testing-the-Waters Communications

None

SCHEDULE 1(a)(xiii)

[Intentionally Omitted]

SCHEDULE 1(a)(xiv)

[Intentionally Omitted]

EXHIBIT A

Form of Lock-Up Agreement

[Intentionally Omitted]

EX-5.1 — OPINION

EX-5.1

Filename: lifeway_ex0501.htm · Sequence: 3

Exhibit 5.1

Kelley Drye & Warren LLP

333 West Wacker Drive

26th Floor

Chicago, Illinois 60606

Tel: (312) 857-7076

May 14, 2026

Lifeway Foods, Inc.

6431 West Oakton

Morton Grove, IL 60053

Ladies and Gentlemen:

We are acting as special counsel to Lifeway Foods,

Inc., an Illinois corporation (the “Company”), in connection with the preparation and filing with the Securities and

Exchange Commission (the “Commission”) of a Registration Statement on Form S-3, No. 333-291148, and a prospectus supplement

thereto dated May 14, 2026 (collectively, the “Registration Statement”), relating to the registration of the resale

of 3,454,756 shares of the Company’s common stock, no par value (the “Shares”), by the Selling Stockholder (as

defined below). This Registration Statement is being filed pursuant to the Cooperation Agreement, dated September 30, 2025 (the “Cooperation

Agreement”), between the Company and Danone USA Public Benefit Corporation f/k/a Danone North America PBC, a Delaware public

benefit corporation (the “Selling Stockholder”).

In connection with this opinion, we have examined

and relied upon copies certified or otherwise identified to our satisfaction of: (i) the Cooperation Agreement; (ii) the Registration

Statement, together with exhibits and schedules thereto, in the form filed with the Commission; (iii) the Company’s Articles of

Incorporation, as amended to date; (iv) the Company’s Second Amended and Restated By-Laws, as amended to date; and (v) the records

of corporate proceedings of the Company relating to the Shares, as made available to us by officers of the Company; and have reviewed

such matters of law as we have deemed necessary or appropriate for the purpose of rendering this opinion.

For purposes of this opinion we have assumed the

authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified

or photostatic copies, and the authenticity of the originals of all documents submitted to us as copies. We have also assumed the legal

capacity of all natural persons, the genuineness of all signatures on all documents examined by us, including signatures made and/or transmitted

using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that any such signed electronic

record shall be valid and as effective to bind the party so signing as a paper copy bearing such party’s handwritten signature.

As to certain factual matters material to the opinion expressed herein, we have relied to the extent we deemed proper upon representations

and certifications as to factual matters of officers and other representatives of the Company. Our opinion expressed below is subject

to the qualification that we express no opinion as to any law other than the Business Corporation Act of the State of Illinois and the

federal laws of the United States of America. Without limiting the foregoing, we express no opinion with respect to the applicability

thereto or effect of municipal laws or the rules, regulations or orders of any municipal agencies within any such state.

Based

upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set forth below, it is our opinion

that the Shares are validly issued, fully paid and non-assessable.

This opinion is limited to the specific issues addressed

herein, and no opinion may be inferred or implied beyond that expressly stated herein. We assume no obligation to revise or supplement

this opinion should the present Business Corporation Act of the State of Illinois or the federal laws of the United States of America

be changed by legislative action, judicial decision or otherwise.

We hereby consent to the filing of this letter as

an exhibit to the Registration Statement and to the reference to our firm under the heading “Legal Matters” in the Registration

Statement. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of

the Securities Act of 1933 or the rules and regulations of the Commission promulgated thereunder.

This opinion is furnished to you in connection with

the filing of the Registration Statement and is not to be used, circulated, quoted or otherwise relied upon for any other purpose.

Very truly yours,

/s/ Kelley Drye & Warren LLP

EX-99.1 — PRESS RELEASE DATED MAY 14, 2026

EX-99.1

Filename: lifeway_ex9901.htm · Sequence: 4

Exhibit 99.1

Lifeway Foods Announces Pricing of Secondary

Underwritten Public Offering of Common Stock

Morton Grove, IL — May 14, 2026 —

Lifeway Foods, Inc. (Nasdaq: LWAY) (“Lifeway” or the “Company”) today announced the pricing of a secondary underwritten

public offering (the “Offering”) of 3,454,756 shares of its common stock (“Common Stock”) by Danone USA Public

Benefit Corporation (the “Selling Stockholder”) at a price to the public of $19.50 per share.

The Offering consists entirely of shares of Common

Stock being sold by the Selling Stockholder and is expected to close on May 19, 2026, subject to customary closing conditions. The Company

is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering. The Company has agreed

to repurchase approximately $5.0 million of the Shares in the Offering at the same per share price to be paid by investors in the Offering

(the “Share Repurchase”). The Offering is not conditioned upon the completion of the Share Repurchase, but the share repurchase

is conditioned upon the completion of the Offering.

BTIG is acting as the sole book-running manager

for the Offering.

The Offering is being made pursuant to a shelf

registration statement on Form S-3 (No. 333-291148) that was previously filed with the Securities and Exchange Commission (“SEC”)

and declared effective by the SEC on December 10, 2025. A preliminary prospectus supplement and accompanying prospectus relating to and

describing the terms of the Offering is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement

and the accompanying prospectus relating to the Offering may also be obtained, when available, by contacting: BTIG, LLC, 65 East 55th

Street, New York, New York 10022, Attn: Syndicate Department, BTIGSyndicateCoverage@btig.com.

This press release does not constitute an offer

to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction

in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Lifeway Foods, Inc.

Lifeway Foods, Inc., which has been recognized

as one of America's Growth Leaders by TIME, as Dairy Foods' Processor of the Year 2025, one of Forbes' Best Small Companies and named

to Inc.'s 2025 Best in Business list in the Best Challenger Brands category, is America's leading supplier of the probiotic, fermented

beverage known as kefir. In addition to its line of drinkable kefir, the Company also produces a variety of cheeses and a ProBugs®

line for kids. Lifeway's tart and tangy fermented dairy products are now sold across the United States, Mexico, United Arab Emirates,

Central America and the Caribbean. Learn how Lifeway is good for more than just you at lifewayfoods.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements”

within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied

statements related to Bel’s expectations regarding the timing and closing of the offering. The words “may,” “will,”

“could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,”

“believe,” “estimate,” “predict,” “project,” “potential,” “continue,”

“seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s

current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events

or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. The

Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The

Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events,

conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ

from those set forth in the forward-looking statements.

Derek Miller

Vice President of Communications, Lifeway Foods

Email: derekm@lifeway.net

General inquiries:

Lifeway Foods, Inc.

Phone: 847-967-1010

Email: info@lifeway.net

GRAPHIC

Filename: image_001.jpg · Sequence: 9

Binary file (4069 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

May 14, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 14, 2026

Entity File Number

000-17363

Entity Registrant Name

LIFEWAY FOODS, INC.

Entity Central Index Key

0000814586

Entity Tax Identification Number

36-3442829

Entity Incorporation, State or Country Code

Entity Address, Address Line One

6431

West Oakton St.

Entity Address, City or Town

Morton

Grove

Entity Address, State or Province

Entity Address, Postal Zip Code

60053

City Area Code

(847)

Local Phone Number

967-1010

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock No Par Value [Member]

Title of 12(b) Security

Common Stock, no par value

Trading Symbol

LWAY

Security Exchange Name

NASDAQ

Preferred Stock Purchase Rights [Member]

Title of 12(b) Security

Preferred Stock Purchase Rights

No Trading Symbol Flag

true

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=LWAY_CommonStockNoParValueMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=LWAY_PreferredStockPurchaseRightsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: